2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, DOI: 10.1002/ejhf.2722.Peer-Reviewed Original ResearchConceptsAngiotensin receptor neprilysin inhibitorMineralocorticoid receptor antagonistsSafety of dapagliflozinHeart failureEjection fractionPrimary outcomeReceptor antagonistRecent guidelinesSodium-glucose cotransporter 2 inhibitorsLower systolic blood pressureBenefit of dapagliflozinPrior HF hospitalizationSacubitril/valsartanCotransporter 2 inhibitorsEffect of dapagliflozinSystolic blood pressureARNI therapyHF hospitalizationCardiovascular deathAdverse eventsHazard ratioBlood pressureSGLT2 inhibitorsPatientsDapagliflozinBlood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER
Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBlood pressureHeart failureSBP categoriesEjection fractionPrimary outcomeKansas City Cardiomyopathy Questionnaire total symptom scoreTreatment effectsSodium-glucose cotransporter 2 inhibitorsBaseline systolic blood pressureBlood pressure-lowering effectHigher systolic blood pressureHigher heart failureClass I recommendationCotransporter 2 inhibitorsPressure-lowering effectTotal symptom scoreCardiovascular outcomesAdverse eventsAntihypertensive effectSecondary outcomesStroke riskI recommendationSymptom scoresCardiovascular disease
2020
1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.Peer-Reviewed Original ResearchObstructive sleep apneaNew-onset obstructive sleep apneaCardiovascular diseaseDohme Corp.Novo Nordisk A/SMundipharma InternationalMerck SharpEli LillyEMPA-REG OUTCOMEIncident obstructive sleep apneaFavorable metabolic effectsSanofi-AventisSystolic blood pressureCoronary artery diseaseType 2 diabetesAdvisory PanelEMPA-REGOSA statusPhilips RespironicsSanofi GenzymeSevere obesityArtery diseaseBlood pressureWaist circumferenceSleep apnea
2019
Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c
Wanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.Peer-Reviewed Original Research
2018
Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry
WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.Peer-Reviewed Original ResearchDiabetes Collaborative RegistryDiabetes mellitusBoehringer Ingelheim PharmaceuticalsJanssen PharmaceuticalsBristol-Myers Squibb CompanyCollaborative RegistryGlaxoSmithKline plcHigh-intensity statin usePfizer IncU.S. adultsBoehringer Ingelheim GmbHLow ASCVD riskRisk factor targetsAmgen Inc.Multiple logistic regressionAmgen IncASCVD preventionEisai Inc.ASCVD riskStatin useBlood pressureDM medicationsMultifactorial interventionMale sexNovo Nordisk A/SEmpagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c
WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.Peer-Reviewed Original ResearchControl of BPLow-density lipoprotein cholesterolRisk of incidentCV risk factorsBlood pressureBoehringer Ingelheim PharmaceuticalsRenal outcomesLipoprotein cholesterolRisk factorsJanssen PharmaceuticalsConventional CV risk factorsEMPA-REG OUTCOME trialBoehringer Ingelheim GmbHDiastolic blood pressureSystolic blood pressureEli LillyAbbVie IncEMPA groupSanofi GenzymeHazard ratioInhibitor empagliflozinRenoprotective roleTime-dependent covariatesOutcome trialsDohme Corp.What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?
INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.Peer-Reviewed Original ResearchTransient ischemic attackDensity lipoprotein cholesterolInsulin resistanceCV benefitsLog HRCardiovascular benefitsLipoprotein cholesterolBlood pressureStroke/transient ischemic attackHigh-sensitivity C-reactive proteinHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMeasures of IRInsulin Resistance InterventionHomeostatic model assessmentDiastolic blood pressureEffect of pioglitazoneSystolic blood pressureC-reactive proteinFavorable effectBoehringer Ingelheim PharmaceuticalsPIO effectIschemic attackNondiabetic patientsHOMA-IR
2008
Cardiovascular risk-benefit ratio of thiazolidinediones
Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.Peer-Reviewed Original ResearchRisk-benefit ratioType 2 diabetes mellitusActual cardiovascular outcomesSurrogates of atherosclerosisDifferential clinical effectsInsulin-sensitizing thiazolidinedionesEffective antihyperglycemic agentCardiovascular eventsCardiovascular outcomesCardiovascular implicationsBlood pressureDiabetes mellitusEndothelial functionHeart failureClinical effectsInsulin resistanceAntihyperglycemic agentsFluid retentionLipid profileThiazolidinedionesPatientsAvailable membersBeneficial impactMellitusT2DM